Novo Nordisk seeks extended approval for diabetes drug in the US

The US FDA will now decide whether to expand the label for Novo Nordisk's drug Ozempic to also include a higher dose of the drug.

Photo: Stine Tidsvilde

Danish pharmaceutical firm Novo Nordisk has submitted a label expansion application for its diabetes drug Ozempic to the US Food and Drug Administration (FDA), according to a company press release.

The application aims at an approval of Ozempic for the treatment of type II diabetes with a dose of 2.0 mg, building on top of the 0.5 mg and 1.0 mg which have already been approved.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs